Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AIM CVE:LPC TSE:OLY NYSEARCA:XLY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMAIM ImmunoTech$9.25+6.9%$9.09$0.06▼$14.93$7.07M0.98559,202 shs8,587 shsLPCLorne Park Capital PartnersC$2.21+0.5%C$1.91C$1.26▼C$2.21C$120.78M-0.035,447 shs15,000 shsOLYOlympia Financial GroupC$122.20-0.7%C$115.68C$92.06▼C$124.00C$294.06M0.271,939 shs2,398 shsXLYConsumer Discretionary Select Sector SPDR Fund$222.17+0.9%$215.69$166.48▼$240.28$22.83B1.183.68 million shs5.62 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMAIM ImmunoTech0.00%+0.83%+11.45%+1.20%-78.08%LPCLorne Park Capital Partners0.00%+0.45%+0.45%+47.33%+30.00%OLYOlympia Financial Group0.00%+0.79%+0.83%+16.71%+24.05%XLYConsumer Discretionary Select Sector SPDR Fund0.00%+0.33%+5.58%+19.83%+16.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMAIM ImmunoTech1.6608 of 5 stars3.50.00.00.03.20.00.0LPCLorne Park Capital PartnersN/AN/AN/AN/AN/AN/AN/AN/AOLYOlympia Financial Group2.6067 of 5 stars2.50.02.50.00.63.31.3XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMAIM ImmunoTech 3.00Buy$275.002,872.97% UpsideLPCLorne Park Capital Partners 0.00N/AN/AN/AOLYOlympia Financial Group 3.00BuyC$147.9121.04% UpsideXLYConsumer Discretionary Select Sector SPDR Fund 2.65Moderate Buy$222.17N/ACurrent Analyst Ratings BreakdownLatest LPC, XLY, OLY, and AIM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OLYOlympia Financial GroupFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$147.91(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMAIM ImmunoTech$146K48.40N/AN/A$0.20 per share46.25LPCLorne Park Capital PartnersC$33.58M3.60C$0.18 per share12.39C$0.55 per share4.02OLYOlympia Financial GroupC$102.64M2.86C$10.48 per share11.66C$16.72 per share7.31XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMAIM ImmunoTech-$28.96M-$24.00N/AN/AN/A-12,594.21%-421.73%-147.54%N/ALPCLorne Park Capital PartnersC$1.78MC$0.0367.79∞N/A5.31%15.06%4.60%N/AOLYOlympia Financial GroupC$24.45MC$10.1612.03∞N/A23.82%64.95%35.88%N/AXLYConsumer Discretionary Select Sector SPDR FundN/AN/A27.10∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMAIM ImmunoTechN/AN/AN/AN/AN/ALPCLorne Park Capital PartnersC$0.031.36%N/A92.02%N/AOLYOlympia Financial GroupC$7.205.89%N/A70.86%N/AXLYConsumer Discretionary Select Sector SPDR Fund$1.820.82%N/AN/AN/ALatest LPC, XLY, OLY, and AIM DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/22/2025OLYOlympia Financial GroupMonthlyC$0.605.95%7/22/20257/31/20257/31/20256/19/2025OLYOlympia Financial GroupMonthlyC$0.606.28%6/19/20256/30/20256/30/20255/21/2025OLYOlympia Financial GroupMonthlyC$0.606.99%5/21/20255/30/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMAIM ImmunoTech0.050.750.75LPCLorne Park Capital Partners82.701.391.93OLYOlympia Financial Group6.003.321.59XLYConsumer Discretionary Select Sector SPDR FundN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMAIM ImmunoTech12.02%LPCLorne Park Capital PartnersN/AOLYOlympia Financial Group1.17%XLYConsumer Discretionary Select Sector SPDR Fund69.93%Insider OwnershipCompanyInsider OwnershipAIMAIM ImmunoTech0.02%LPCLorne Park Capital Partners44.76%OLYOlympia Financial Group34.63%XLYConsumer Discretionary Select Sector SPDR FundN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMAIM ImmunoTech20764,00068.74 millionNot OptionableLPCLorne Park Capital PartnersN/A54.65 millionN/ANot OptionableOLYOlympia Financial Group3252.41 millionN/ANot OptionableXLYConsumer Discretionary Select Sector SPDR Fund147,000102.75 millionN/ANot OptionableLPC, XLY, OLY, and AIM HeadlinesRecent News About These CompaniesThe Market Rally Is Gaining Momentum—Don’t Get Left Behind (XLY)...July 17 at 5:25 PM | marketbeat.com5 Sector ETFs Set to Power Q2 Earnings GrowthJuly 10, 2025 | zacks.comS&P 500 consumer discretionary sector jumps 8.9% in Q2, Royal Caribbean Cruises, Carnival, Lululemon Athletica among top moversJuly 3, 2025 | seekingalpha.comWeekly Economic Snapshot: Record Highs Amid Rising Inflation & Conflicting SentimentJune 30, 2025 | etftrends.comENorwegian Cruise Line Stock: Is NCLH Underperforming the Consumer Discretionary Sector?June 26, 2025 | msn.comConsumer Discretionary Select Sector SPDR ETF declares quarterly distribution of $0.4470June 23, 2025 | msn.comAmcor Stock: Is AMCR Underperforming the Consumer Discretionary Sector?June 23, 2025 | finance.yahoo.comConsumer Rebound Boosts Outlook for Discretionary ETFsJune 16, 2025 | zacks.comWeekly Economic Snapshot: Inflation Edges Up While Sentiment ReboundsJune 16, 2025 | etftrends.comESector ETFs Set to Gain as Inflation Cools in MayJune 12, 2025 | zacks.comIs Consumer Discretionary a Dead End? These 3 Stocks Say No (XLY)...June 11, 2025 | marketbeat.comNintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive? (XLY)...June 11, 2025 | marketbeat.comConsumer Discretionary ETFs Set for a Comeback?June 11, 2025 | zacks.comWeekly Economic Snapshot: Inflation Cools While Sentiment Cautiously ClimbsJune 2, 2025 | etftrends.comEShould You Invest in the Consumer Discretionary Select Sector SPDR ETF (XLY)?June 2, 2025 | zacks.comWeekly Economic Snapshot: Inflation Relief Meets Consumer WoesMay 19, 2025 | etftrends.comE3 Dividend-Friendly Consumer Discretionary Stocks With UpsideMay 19, 2025 | dividendstocks.comDMost and least shorted S&P 500 consumer discretionary stocks in AprilMay 18, 2025 | seekingalpha.com3 ETF Strategies to Follow on Temporary U.S.-China Trade DealMay 12, 2025 | zacks.comOil Slumps to Below $60: ETFs to GainMay 5, 2025 | zacks.comWeekly Economic Snapshot: Solid Jobs Amid GDP Contraction & Crashing ConfidenceMay 5, 2025 | etftrends.comENew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseThe Market Rally Is Gaining Momentum—Don’t Get Left BehindBy Thomas Hughes | July 17, 2025View The Market Rally Is Gaining Momentum—Don’t Get Left BehindLPC, XLY, OLY, and AIM Company DescriptionsAIM ImmunoTech NYSE:AIM$9.25 +0.60 (+6.94%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$9.21 -0.04 (-0.44%) As of 07/18/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Lorne Park Capital Partners CVE:LPCC$2.21 +0.01 (+0.45%) As of 07/15/2025Lorne Park Capital Partners Inc., together with its subsidiaries, provides portfolio management services to investors, estates, trusts, endowments, and foundations in Canada and the United States. It also offers insurance agency services. The company was founded in 2009 and is based in Oakville, Canada.Olympia Financial Group TSE:OLYC$122.20 -0.80 (-0.65%) As of 07/18/2025 03:59 PM EasternOlympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.Consumer Discretionary Select Sector SPDR Fund NYSEARCA:XLY$222.17 +1.95 (+0.89%) Closing price 07/18/2025 04:10 PM EasternExtended Trading$222.27 +0.10 (+0.05%) As of 07/18/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Consumer Discretionary Select Sector SPDR Fund seeks to provide investment results that correspond generally to the price and yield performance of the Consumer Discretionary Select Sector Index (the Index). The Index includes companies from the following industries, media; retail (specialty, multiline, Internet and catalog); hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure equipment and products; and diversified consumer services. The Fund's investment advisor is SSgA Funds Management, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
